ArticleJournal of the American Heart Association2018
Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low-Density Lipoprotein Cholesterol.
Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial.American heart journal · 2026Trial
- Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition.European heart journal. Cardiovascular pharmacotherapy · 2023Trial
- Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia.Journal of the American Heart Association · 2020Trial
- Metabolic and redox pathway dysregulation in HIV-associated coronary endothelial dysfunction.American journal of physiology. Heart and circulatory physiology · 2026Observational
- A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries.Frontiers in pharmacology · 2026Review
- Metabolic and Redox Pathway Dysregulation in HIV-Associated Coronary Endothelial Dysfunction: Insights into Early-Phase HIV Vascular Dysfunction.bioRxiv : the preprint server for biology · 2025Article
- Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial.JACC. Basic to translational science · 2025Article
- Lipoprotein(a) and Cardiovascular Disease in People Living With HIV: The Next Horizon.Journal of the American Heart Association · 2024Article
- Lipoprotein(a) Is Elevated and Inversely Related to Coronary Endothelial Function in People With HIV.Journal of the American Heart Association · 2024Article
- Transgender Women with HIV Demonstrate Unique Non-Alcoholic Fatty Liver Disease Profiles.Transgender health · 2024Article
- Homocysteine modifies the association of coronary stenosis and HIV infection in an inner city African American population.International journal of STD & AIDS · 2024Article
- Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease.Circulation research · 2024Review
- Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.Signal transduction and targeted therapy · 2024Review
- Endothelial injury and decline in lung function in persons living with HIV: a prospective Danish cohort study including 698 adults.Frontiers in medicine · 2024Article
- Coronary artery endothelial function and aging in people with HIV and HIV-negative individuals.American journal of physiology. Heart and circulatory physiology · 2023Article
- Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterol.Circulation. Cardiovascular imaging · 2023Article
- Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements-A Narrative Review.Nutrients · 2023Review
- Aortic aneurysms and markers of platelet activation, hemostasis, and endothelial disruption in people living with HIV.Frontiers in immunology · 2023Article
- Effect of Sex on Coronary Endothelial Dysfunction in People Living With HIV.Journal of the American Heart Association · 2022Article
- PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?Reviews in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Background HIV + people are at increased risk of coronary artery disease, but the responsible mechanisms are incompletely understood. Proprotein convertase subtilisin/kexin type 9 ( PCSK 9) is traditionally recognized for its importance in cholesterol metabolism; however, recent data suggest an additional, low-density lipoprotein receptor-independent adverse effect on endothelial cell inflammation and function. We tested the hypotheses that PCSK 9 levels are increased and that abnormal coronary endothelial function is related to PCSK 9 serum levels in HIV + individuals. Methods and Results Forty-eight HIV + participants receiving antiretroviral therapy with suppressed viral replication, without coronary artery disease, and 15 age- and low-density lipoprotein cholesterol-matched healthy HIV- subjects underwent magnetic resonance imaging to measure coronary endothelial function, quantified as percentage change in coronary artery cross-sectional area during isometric handgrip exercise, an endothelial-dependent stressor; and blood was obtained for serum PCSK 9 and systemic vascular biomarkers. Data are presented as mean±SD. Mean serum PCSK 9 was 65% higher in the HIV + subjects (302±146 ng/ mL ) than in the HIV - controls (183±52 ng/ mL , P<0.0001). Coronary endothelial function was significantly reduced in the HIV + versus HIV - subjects (percentage change in coronary artery cross-sectional area, 2.9±9.6% versus 11.1±3.7%; P<0.0001) and inversely related to PCSK 9 ( R=-0.51, P<0.0001). Markers of endothelial activation and injury, P-selectin and thrombomodulin, were also significantly increased in the HIV + subjects; and P-selectin was directly correlated with serum PCSK 9 ( R=0.31, P=0.0144). Conclusions Serum PCSK 9 levels are increased in treated HIV + individuals and are associated with abnormal coronary endothelial function, an established measure of vascular health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.